Sterne Kessler’s biopharma industry team counsels clients worldwide on IP strategy across medical and healthcare related applications of biotechnology.
Sterne Kessler works closely with biologic drug companies to develop robust, defensible patent portfolios that create substantial shareholder value. Our clients' innovations span therapeutic antibodies, vaccines, nanomedicines, and related diagnostics that make personalized medicine a reality. We know biopharmaceuticals and we have been on the forefront of biopharma intellectual property from the very start.
The biotechnology practice at Sterne Kessler was established by Dr. Jorge Goldstein just as the biotech revolution was getting started. As the market expanded, so did our practice. We represent companies and research institutes of all sizes and levels, and they span, among others, the areas of:
- Molecular and cell biology
- Nanomedicine
- Pharmacogenomics
- Vaccines
- Therapeutic antibodies
- Nutraceuticals
- Biologics and biosimilars
We prepare and prosecute patent applications before U.S. and foreign patent offices; conduct interferences, IPRs, and other patent office litigation; and lead district court and U.S. International Trade Commission litigations. For those collaborating, licensing, or commercializing innovations, we provide counseling regarding agreements and develop freedom to operate opinions. Additionally, we conduct IP due diligence to support our clients who are licensing or investing in promising new technologies.
We meet our clients' needs with an integrated team of more than 70 attorneys and technical staff with advanced training that cuts across a variety of disciplines including:
- Biochemistry
- Bioinformatics
- Computer-aided drug design
- Enzymology
- Gene therapy
- Genetics
- Genomics
- Immunology
- Medicinal chemistry
- Microbiology
- Molecular biology
- Organic chemistry
- Pharmacology
- Physical chemistry
- Virology
